- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01225523
Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus
Perioperative Versus Preoperative Chemotherapy With Surgery in Patients With Locoregional Squamous Carcinoma of Esophagus
Study Overview
Status
Intervention / Treatment
Detailed Description
Perioperative chemotherapy has been shown to significantly improve the R0 resection rate, the disease free survival and the overall survival in patients with adenocarcinoma of the esophagus, the gastroesophageal junction and the stomach. Therefore, perioperative chemotherapy is the new therapeutic standard (Cunningham NEJM 2006, MRC, Lancet 2002, Boige ASCO 2007). The best-evaluated regime is the combination of Epirubicin, Cisplatin and 5-FU (ECF) (Cunningham, NEJM 2007). Cisplatin and 5-FU are considered to be the most important components to form the cornerstone of this regime.
Paclitaxel is a new and highly active cytotoxic agent. In a randomized phase II study, the dual combination of Paclitaxel and 5-FU seemed to show similar effects as ECF, administered as first line treatment. The triplet combination of Paclitaxel, Cisplatin and 5-FU has significantly superior efficacy than a combination of Cisplatin und 5-FU (Van Cutsem, JCO 2007).
It has been shown that Capecitabine is more active than 5-FU and can replace intravenous 5-FU in the combination with Cisplatin in the treatment of esophageal cancer. Capecitabine therefore is FDA approved for esophageal cancer (Cunningham, ASCO 2006, Kang ASCO 2006).It seems reasonable to optimize perioperative chemotherapy by including this modern chemotherapeutics.
In this study, patients with squamous carcinoma of esophagus and gastroesophageal junction who seem operable with curative intent according to oncological and surgical assessment are treated with 2 preoperative cycles of PCF followed by surgical resection, followed by 2 postoperative cycles of PCF. Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose is defined as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen Postoperative chemotherapy will start within 4-6 weeks after the operation. 3 weeks after the end of the last chemotherapy the final investigation (end of study visit) will be done.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- First Affiliated Hospital of College of Medicine of Xi'an Jiao Tong University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- histologically confirmed esophageal cancer (squamous carcinoma) measurable, non-metastatic disease
- no previous cancer therapy (chemotherapy, radiotherapy or resection)
- life expectancy > 3 months
- age > 18 years
- WHO Status ≤ 1
- Intended curative resection according to evaluation of an experienced surgeon
- Negative pregnancy blood test at screening but not earlier than 72 hours prior to start of chemotherapy for women with child bearing potential
- Adequate haematologic function and liver and renal function: neutrophils > 1.5×109/L; thrombocytes > 100×109/L; haemoglobin > 10 g/dl, creatinine clearance > 60 ml/min (calculated according to Cockroft and Gault), total bilirubin < 1.0×UNL; AST and ALT < 1.5×UNL, AP < 2.5×UNL
- Complete staging within 3 weeks prior to start of treatment (CT-scan of thorax and abdomen, endosonography, gastroscopy)
- Ability to keep appointments and follow the study protocol
- By CT-scan, endoscopy or endosonography measurable or evaluable disease
Exclusion Criteria:
- Former therapy of cancer (operation, chemo- or radiotherapy)
- Diagnosis of another cancer in the last 5 years prior to study entry which has not been cured by operation only (exception in-situ-carcinoma of the cervix or cured non-melanomatose skin cancer)
- Known contraindication to the planned chemotherapeutics
- Presence of distant metastases
- Anamnestic known serious disease or other concomitant diseases that affect participation in this study, such as:
oInstable cardiac disease: symptomatic heart failure, symptomatic coronary artery disease, ventricular cardiac arrhythmia not well controlled with medication, myocardial infarction or resuscitation within 6 month before study oActive infection necessitating systemic therapy or uncontrolled infection oInterstitial lung diseases (for example: pneumonitis or fibrosis of the lung) and indication for interstitial lung disease in chest x-ray or CT-scan respectively oActive inflammatory bowel disease or other bowel diseases which provoke chronic diarrhea (defined as > 4 bowel movements per day) oNeurological or psychiatric disease including dementia, epilepsy or untreated, symptomatic brain metastases oLimited hearing ability
- Presence of upper GI obstruction, leading to inability to swallow ground tablets
- Presence of acute or chronic systemic infection
- Presence of a bowel obstruction within the last 30 days
- Pregnant or lactating women or women with child bearing potential and men without adequate contraception (high effective contraception, defined as Pearl Index < 1) like birth control pill, hormone spiral, hormone implant, transdermal patch, a combination of two barrier methods (condom and diaphragm), realized sterilization or sexual abstinence during the study and at least for 3 months after the last infusion
- Any other situation which may lead to an unacceptable high risk for the patient, when he participates in the study
- Parallel treatment in another clinical study or prior participation in this study
- Treatment with any other therapy against the tumor or any parallel radiation
- Symptomatic peripheral neuropathy NCI-CTCAE degree > 2
- Intolerance to the study medication
- Detention in a psychiatric unit or imprisonment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Preoperative chemotherapy followed by surgery
|
Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
|
ACTIVE_COMPARATOR: Perioperative chemotherapy with surgery
|
Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival
Time Frame: 3 years
|
3 years
|
Overall survival rate
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Operative and postoperative complication rate
Time Frame: Within 30 days after surgery
|
Within 30 days after surgery
|
Rate of local recurrences and metastasis
|
|
30-day mortality
Time Frame: After date of surgery
|
After date of surgery
|
Pathological remission rate
Time Frame: After 2 cycles of preoperative chemotherapy (2 month)
|
After 2 cycles of preoperative chemotherapy (2 month)
|
Resectability rate
Time Frame: After 2 cycles of preoperative chemotherapy (2 month)
|
After 2 cycles of preoperative chemotherapy (2 month)
|
Toxicity of preoperative and postoperative chemotherapy
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Esophageal Neoplasms
- Esophageal Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Cisplatin
- Fluorouracil
- Capecitabine
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- ZY-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Carcinoma of Esophagus
-
Jules Bordet InstituteInnate PharmaWithdrawnAdenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the EsophagusBelgium
-
Nang Kuang Pharmaceutical Co., Ltd.TerminatedLocalized Squamous Cell Carcinoma of the EsophagusTaiwan
-
Huai'an First People's HospitalActive, not recruitingEsophagus Squamous Cell CarcinomaChina
-
Institut für Klinische Krebsforschung IKF GmbH...Eli Lilly and Company; Trium Analysis Online GmbHCompletedSquamous Cell Carcinoma of the EsophagusGermany
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalCompletedAdenocarcinoma of Esophagus | Squamous Cell Carcinoma of EsophagusUnited States
-
Yonsei UniversityActive, not recruitingHistologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard TreatmentKorea, Republic of
-
Peking University Cancer Hospital & InstituteUnknownPerformance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal LesionsEsophageal Squamous Cell Carcinoma | Mild Dysplasia of Esophagus | Moderate Dysplasia of Esophagus | Severe Dysplasia of Esophagus | Carcinoma in Situ of EsophagusChina
-
University of Michigan Rogel Cancer CenterTerminatedMetastatic or Recurrent Squamous Cell Carcinoma of the EsophagusUnited States
-
Zhejiang UniversityWithdrawnSquamous Cell Carcinoma of EsophagusChina
-
All India Institute of Medical Sciences, New DelhiUnknown
Clinical Trials on Paclitaxel; Cisplatin; 5-Fluorouracil
-
Fudan UniversityFujian Cancer Hospital; Affiliated Hospital of Jiangnan University; First Affiliated... and other collaboratorsCompletedEsophageal Squamous Cell CarcinomaChina
-
Peking UniversityTerminated
-
Sun Yat-sen UniversityUnknownNasopharyngeal Carcinoma | ChildrenChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownSquamous Cell Carcinoma of the Head and NeckChina
-
National Taiwan University HospitalCompleted
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedEsophageal CancerUnited States
-
Shantou University Medical CollegeWithdrawn
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
Seoul National University HospitalKorean Cancer Study Group; Ministry of Health & Welfare, KoreaCompletedChemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric CancerGastric CancerKorea, Republic of